EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elucidating the Mechanism of Oridonin in Treating Hepatocellular Carcinoma: Network Pharmacology and Experimental Validation

Long Li, Xiaodi Guo, Gangqiang Wang, Jing Zhang, Jin Wang, Shan Miao, Yang Sun, Shanbo Ma, Xiaopeng Shi

Journal of Cellular and Molecular Medicine · 2026-06 · 30 (11)

DOI: 10.1111/jcmm.71180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 03.06.2026. Verfasst von Long Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Diterpenes, Kaurane, Carcinoma, Hepatocellular, Liver Neoplasms, Network Pharmacology. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Institution, Xijing Hospita.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oridonin, a bioactive diterpenoid derived from Rabdosia rubescens, has significant anti‐tumour activity. Although previous studies have shown that oridonin has anti‐liver cancer potential, the molecular mechanism of its treatment of hepatocellular carcinoma (HCC) still needs to be further investigated. This study utilized network pharmacology, molecular docking, and molecular dynamics simulations (MDS) to elucidate the mechanisms by which oridonin exerts its therapeutic effects on HCC. The findings were then validated by in vitro experiments. Initially, potential targets of oridonin for HCC were identified through online database retrieval. The mechanisms of oridonin in resisting HCC were then elucidated via integrated protein–protein interaction (PPI) network analysis, GO and KEGG enrichment analysis. Subsequently, these findings were confirmed through molecular docking, MDS and the in vitro experiments. A total of 273 intersecting targets were identified. Subsequently, PPI network analysis was performed, leading to the identification of 10 core targets. Molecular docking studies between these targets and oridonin suggested that PIK3R1, EGFR, AKT1, and JAK2 might be key targets. Further MDS demonstrated a strong interaction between oridonin and these key targets. Subsequent in vitro experiments revealed that oridonin significantly affects the cell cycle and induces apoptosis in HCC cells. Furthermore, oridonin significantly inhibits the expression of key targets within the EGFR/PI3K/AKT signalling pathway. These findings suggest that oridonin may exert anti‐cancer effects through the EGFR/PI3K/AKT signalling pathway, providing a robust theoretical foundation for its clinical application and mechanistic investigation in HCC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diterpenes, KauraneCarcinoma, HepatocellularLiver NeoplasmsNetwork PharmacologyHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein Interaction MapsCell ProliferationApoptosisSignal TransductionProto-Oncogene Proteins c-aktErbB ReceptorsCell Line, TumorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

EGFR/PI3K/AKTdynamics simulationhepatocellular carcinomamolecular dockingnetwork pharmacologyoridonin

Substanzen

Diterpenes, KauraneoridoninProto-Oncogene Proteins c-aktErbB Receptors

Autor:innen und Institutionen

  • Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Department of Clinical Laboratory, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, Fourth Military Medical University, Xi'an, China.

Förderung

  • Research Institution, Xijing Hospita

Zitieren

APA

Li, L., Guo, X., Wang, G., Zhang, J., Wang, J., Miao, S., Sun, Y., Ma, S., & Shi, X. (2026). Elucidating the Mechanism of Oridonin in Treating Hepatocellular Carcinoma: Network Pharmacology and Experimental Validation. Journal of Cellular and Molecular Medicine, 30(11). https://doi.org/10.1111/jcmm.71180

Vancouver

Li L, Guo X, Wang G, Zhang J, Wang J, Miao S, et al. Elucidating the Mechanism of Oridonin in Treating Hepatocellular Carcinoma: Network Pharmacology and Experimental Validation. Journal of Cellular and Molecular Medicine. 2026;30(11). doi:10.1111/jcmm.71180

BibTeX
@article{Li2026,
  author = {Li, Long and Guo, Xiaodi and Wang, Gangqiang and Zhang, Jing and Wang, Jin and Miao, Shan and Sun, Yang and Ma, Shanbo and Shi, Xiaopeng},
  title = {Elucidating the Mechanism of Oridonin in Treating Hepatocellular Carcinoma: Network Pharmacology and Experimental Validation},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {11},
  doi = {10.1111/jcmm.71180}
}
Kostenlos starten →